Orditura M, Galizia G, Lieto E, De Vita F, Ciardiello F. Treatment of esophagogastric junction carcinoma: An unsolved debate. World J Gastroenterol 2015; 21(15): 4427-4431 [PMID: 25914451 DOI: 10.3748/wjg.v21.i15.4427]
Corresponding Author of This Article
Michele Orditura, MD, PhD, Division of Medical Oncology, Department of Internal and Experimental Medicine “F. Magrassi”, School of Medicine, Second University of Naples, c/o II Policlinico, Edificio 3, Via Pansini, 5, 80131 Naples, Italy. michele.orditura@unina2.it
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 21, 2015; 21(15): 4427-4431 Published online Apr 21, 2015. doi: 10.3748/wjg.v21.i15.4427
Treatment of esophagogastric junction carcinoma: An unsolved debate
Michele Orditura, Gennaro Galizia, Eva Lieto, Ferdinando De Vita, Fortunato Ciardiello
Michele Orditura, Ferdinando De Vita, Fortunato Ciardiello, Division of Medical Oncology, Department of Internal and Experimental Medicine “F. Magrassi”, School of Medicine, Second University of Naples, 80131 Naples, Italy
Gennaro Galizia, Eva Lieto, Division of Surgical, Department of Anesthesiological, Surgical and Emergency Sciences, School of Medicine, Second University of Naples, 80131 Naples, Italy
Author contributions: All authors contributed equally to this work.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Michele Orditura, MD, PhD, Division of Medical Oncology, Department of Internal and Experimental Medicine “F. Magrassi”, School of Medicine, Second University of Naples, c/o II Policlinico, Edificio 3, Via Pansini, 5, 80131 Naples, Italy. michele.orditura@unina2.it
Telephone: +39-815-666723 Fax: +39-815-666732
Received: November 13, 2014 Peer-review started: November 15, 2014 First decision: December 26, 2014 Revised: January 2, 2015 Accepted: March 18, 2015 Article in press: March 19, 2015 Published online: April 21, 2015 Processing time: 157 Days and 16 Hours
Abstract
The incidence of esophagogastric junction adenocarcinoma (AEG) is increasing worldwide. Barrett’s esophagus (BE) associated with dysplasia is the main risk factor for the development of cancer. Currently, screening programs to individuate and eradicate BE represent the best way to reduce AEG cancer. Several endoscopic approaches are here discussed. Surgical strategies for different types of AEG cancer are now fairly standardized, and multidisciplinary strategies using chemotherapy or chemoradiotherapy may improve the outcome of these patients. Here we briefly discuss the keypoints, main topics, and critical issues, according to accumulating evidence and taking into account our own experience.
Core tip: Barrett’s esophagus (BE) associated with dysplasia is the main risk factor for the development of esophagogastric junction adenocarcinoma (AEG). Currently, screening programs to individuate and eradicate BE represent the best way to reduce AEG cancer. We aim to discuss several endoscopic approaches, surgical strategies for different types of AEG cancer, and multidisciplinary strategies using chemotherapy or chemoradiotherapy may improve the outcome of AEG patients.
